Posts by Gina
Aspira Receives $1.5 million Milestone Payment from the ARPA-H Sprint for Women’s Health Award
The Company Successfully Reaches the Second Milestone of ARPA-H $10 Million Award AUSTIN, TX / ACCESS Newswire / March 31, 2025 / Aspira Women’s Health Inc. (“Aspira”) (NASDAQ:AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the second development milestone of its Advanced Research Projects Agency…
Read MoreAspira Women’s Health Reports Fourth Quarter and Full Year 2024 Financial Results
Record 2024 OvaSuite revenue of $9.2 million and volume of 24,305 units sold AUSTIN, TX / ACCESS Newswire / March 27, 2025 / Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq:AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year…
Read MoreAspira Women’s Health Announces Closing of $1.37 Million Private Placement of Convertible Notes
AUSTIN, TX / ACCESS Newswire / March 11, 2025 / Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ:AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into a securities purchase agreement dated March 6, 2025, pursuant to which the Company has sold and issued…
Read MoreAspira Women’s Health Submits Request for Withdrawal of Form S-1 Registration Statement
AUSTIN, TX / ACCESS Newswire / February 13, 2025 / Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ:AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the “SEC”) of the Company’s Registration Statement on…
Read MoreAspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the Advanced Research…
Read MoreAspira Women’s Health Receives Approval from New York State Department of Health for OvaWatch®
New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that…
Read MoreAspira Women’s Health’s Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women’s Health (NPWH) Women’s Healthcare Conference
Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the 27th Annual National Association of Nurse Practitioner’s in Women’s Health (NPWH) Woman’s Healthcare…
Read More